SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

Search

Pharma Mar SA

Geschlossen

79.8 1.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

78.5

Max

80.75

Schlüsselkennzahlen

By Trading Economics

Einkommen

-13M

-3.9M

Verkäufe

-9.5M

39M

KGV

Branchendurchschnitt

70

50.291

EPS

-0.22

Dividendenrendite

0.93

Gewinnspanne

-10.047

Angestellte

500

EBITDA

-16M

-1.1M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+37.88% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.93%

2.40%

Nächstes Ergebnis

29. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

23M

1.4B

Vorheriger Eröffnungskurs

78.4

Vorheriger Schlusskurs

79.8

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Pharma Mar SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Juni 2025, 23:49 UTC

Ergebnisse

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. Juni 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. Juni 2025, 21:30 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. Juni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. Juni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. Juni 2025, 23:34 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. Juni 2025, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. Juni 2025, 23:30 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. Juni 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. Juni 2025, 23:19 UTC

Akquisitionen, Fusionen, Übernahmen

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. Juni 2025, 22:06 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:15 UTC

Ergebnisse

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. Juni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 20:52 UTC

Ergebnisse

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. Juni 2025, 20:51 UTC

Ergebnisse

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pharma Mar SA Prognose

Kursziel

By TipRanks

37.88% Vorteil

12-Monats-Prognose

Durchschnitt 108.998 EUR  37.88%

Hoch 110 EUR

Tief 108 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pharma Mar SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

72.75 / 74.3Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.